Literature DB >> 33603771

C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases.

Weina Wang1, Liyan Shui1, Yanning Liu1, Min Zheng1.   

Abstract

Previous studies have reported an important role of c-kit in embryogenesis and adulthood. Activation of the SCF/KIT signal transduction pathway is customarily linked to cell proliferation, migration and survival thus influence hematopoiesis, pigmentation, and spermatogenesis. The role of c-kit in the liver is controversial, it is however argued that it is a double-edged sword in liver regeneration and diseases. First, liver c-kit+ cells, including oval cells, bile epithelial cells, and part of hepatocytes, participate in liver tissue repair by regenerating target cells according to the type of liver injury. At the same time, c-kit+ mast cells, act as immature progenitors in circulation, playing a critical role in liver fibrosis. Furthermore, c-kit is also a proto-oncogene. Notably, c-kit overexpression regulates gastrointestinal stromal tumors. Various studies have explored on c-kit and hepatocellular carcinoma, nevertheless, the intricate roles of c-kit in the liver are largely understudied. Herein, we extensively summarize previous studies geared toward providing hints for future clinical and basic research.
Copyright © 2021 Wang, Shui, Liu and Zheng.

Entities:  

Keywords:  HCC; c-kit; liver disease; liver regeneration; stem cell

Year:  2021        PMID: 33603771      PMCID: PMC7884772          DOI: 10.3389/fgene.2021.598855

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  102 in total

1.  Fibrosis in small syngeneic rat liver grafts because of damaged bone marrow stem cells from chronic alcohol consumption.

Authors:  Masayuki Hisada; Xiuying Zhang; Yoshihiro Ota; Andrew M Cameron; James Burdick; Bin Gao; George Melville Williams; Zhaoli Sun
Journal:  Liver Transpl       Date:  2017-10-27       Impact factor: 5.799

2.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.

Authors:  Mina Komuta; Bart Spee; Sara Vander Borght; Rita De Vos; Chris Verslype; Raymond Aerts; Hirohisa Yano; Tetsuya Suzuki; Masanori Matsuda; Hideki Fujii; Valeer J Desmet; Masamichi Kojiro; Tania Roskams
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

3.  Single-cell gene profiling and lineage tracing analyses revealed novel mechanisms of endothelial repair by progenitors.

Authors:  Jiacheng Deng; Zhichao Ni; Wenduo Gu; Qishan Chen; Witold Norbert Nowak; Ting Chen; Shirin Issa Bhaloo; Zhongyi Zhang; Yanhua Hu; Bin Zhou; Li Zhang; Qingbo Xu
Journal:  Cell Mol Life Sci       Date:  2020-03-13       Impact factor: 9.261

4.  The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role?

Authors:  A Mukhopadhyay; D V Do; C T Ong; Y T Khoo; J Masilamani; S Y Chan; A S Vincent; P K Wong; C P Lim; X Cao; I J Lim; T T Phan
Journal:  Br J Dermatol       Date:  2010-12-22       Impact factor: 9.302

5.  Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.

Authors:  F Eckel; S von Delius; M Mayr; M Dobritz; F Fend; C Hosius; E Schleyer; E Schulte-Frohlinde; R M Schmid; C Lersch
Journal:  Oncology       Date:  2005-11-24       Impact factor: 2.935

6.  Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells.

Authors:  Tümen Mansuroglu; Daniel Baumhoer; Jozsef Dudas; Florian Haller; Silke Cameron; Thomas Lorf; László Füzesi; Giuliano Ramadori
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 2.566

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  Function of oval cells in hepatocellular carcinoma in rats.

Authors:  Chi-Hua Fang; Jia-Qing Gong; Wei Zhang
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  In vitro proliferation and differentiation of hepatic oval cells and their potential capacity for intrahepatic transplantation.

Authors:  Z Li; J Chen; L Li; J H Ran; J Liu; T X Gao; B Y Guo; X H Li; Z H Liu; G J Liu; Y C Gao; X L Zhang
Journal:  Braz J Med Biol Res       Date:  2013-07-30       Impact factor: 2.590

View more
  3 in total

Review 1.  Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers.

Authors:  Hiroshi Fukushima; Baris Turkbey; Peter A Pinto; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancers (Basel)       Date:  2022-06-17       Impact factor: 6.575

2.  Molecular networks of hepatoblastoma predisposition and oncogenesis in Beckwith-Wiedemann syndrome.

Authors:  Natali S Sobel Naveh; Emily M Traxler; Kelly A Duffy; Jennifer M Kalish
Journal:  Hepatol Commun       Date:  2022-05-04

3.  Myelosuppression Alleviation and Hematopoietic Regeneration by Tetrahedral-Framework Nucleic-Acid Nanostructures Functionalized with Osteogenic Growth Peptide.

Authors:  Tianxu Zhang; Mi Zhou; Dexuan Xiao; Zhiqiang Liu; Yueying Jiang; Maogeng Feng; Yunfeng Lin; Xiaoxiao Cai
Journal:  Adv Sci (Weinh)       Date:  2022-07-26       Impact factor: 17.521

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.